Inhaled allergen bronchoprovocation tests

Diamant, Zuzana; Gauvreau, Gail M.; Cockcroft, Don; Boulet, Louis‐Philippe; Sterk, Peter J.; Jongh, Franciscus H.C. de; Dahlén, B.; O'Byrne, Paul M.

doi:10.1016/j.jaci.2013.08.023

Cited by 108 publications

(153 citation statements)

References 116 publications

Supporting

Mentioning

147

Contrasting

Unclassified

Order By: Relevance

“…19,25 All new therapeutic approaches targeting pathways of Th2 cytokines, such as interleukin-4, 26-28 interleukin-5, 29-31 interleukin-13, 32,33 and thymic stromal lymphopoietin (TSLP), 34 which are now in later stages of development, were successful in attenuating the late asthmatic response in early clinical trials. In this study, treatment with SB010 significantly improved lung function during both early and late asthmatic responses after allergen inhalation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Allergen-Induced Asthmatic Responses Modified by a GATA3-Specific DNAzyme

et al. 2015

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…19 Inhaled-allergen challenges were administered in the identical manner before randomization (pretreatment) and after the 28-day study period (posttreatment). 20 Serial spirometric measurements were performed repeatedly in accordance with recent guidelines.…”

Section: Methodsmentioning

confidence: 99%

Allergen-Induced Asthmatic Responses Modified by a GATA3-Specific DNAzyme

et al. 2015

View full text Add to dashboard Cite

“…(38) The current standard of care in asthma, inhaled b-agonist and steroid combination treatments, have a beneficial inhibition of the early asthmatic response (EAR) and the late asthmatic response (LAR), respectively. (39) Steroids predominantly dampen inflammation in the lungs by repressing the transcription of inflammatory mediators (40) that are important in the LAR, (41) and have little effect on the EAR. (42) b-Agonists predominantly relax airway smooth muscle and can reverse bronchoconstriction present in the EAR, but chronic use can exacerbate the decrements in lung function during the LAR.…”

Section: Discussionmentioning

confidence: 99%

Btk Inhibitor RN983 Delivered by Dry Powder Nose-only Aerosol Inhalation Inhibits Bronchoconstriction and Pulmonary Inflammation in the Ovalbumin Allergic Mouse Model of Asthma

Phillips

Renteria

Burns

et al. 2016

Journal of Aerosol Medicine and Pulmonary Drug Delivery

View full text Add to dashboard Cite

Background: In allergen-induced asthma, activated mast cells start the lung inflammatory process with degranulation, cytokine synthesis, and mediator release. Bruton's tyrosine kinase (Btk) activity is required for the mast cell activation during IgE-mediated secretion. Methods: This study characterized a novel inhaled Btk inhibitor RN983 in vitro and in ovalbumin allergic mouse models of the early (EAR) and late (LAR) asthmatic response. Results: RN983 potently, selectively, and reversibly inhibited the Btk enzyme. RN983 displayed functional activities in human cell-based assays in multiple cell types, inhibiting IgG production in B-cells with an IC 50 of 2.5 -0.7 nM and PGD 2 production from mast cells with an IC 50 of 8.3 -1.1 nM. RN983 displayed similar functional activities in the allergic mouse model of asthma when delivered as a dry powder aerosol by nose-only inhalation. RN983 was less potent at inhibiting bronchoconstriction (IC 50 (RN983) ¼ 59 lg/kg) than the bagonist salbutamol (IC 50 (salbutamol) ¼ 15 lg/kg) in the mouse model of the EAR. RN983 was more potent at inhibiting the antigen induced increase in pulmonary inflammation (IC 50 (RN983) ¼ <3 lg/kg) than the inhaled corticosteroid budesonide (IC 50 (budesonide) ¼ 27 lg/kg) in the mouse model of the LAR. Conclusions: Inhalation of aerosolized RN983 may be effective as a stand-alone asthma therapy or used in combination with inhaled steroids and b-agonists in severe asthmatics due to its potent inhibition of mast cell activation.

show abstract

“…Before starting allergen-specific immunotherapy SPTs have to be performed [10][11][12][13][14]. Nasal and bronchial provocation test are indicated for patients with typical clinical symptoms and signs of allergic rhinitis and/ or asthma but with negative in vivo skin prick tests [15]. Those tests should be performed exclusively by a well-trained staff at the allergy departments.…”

Section: Diagnostic Tools and Monitoringmentioning

confidence: 99%

Current Issues on Immunotherapy in Children

Djuric-Filipovic¹,

Živanović²,

Kostić³

et al. 2017

Allergen

View full text Add to dashboard Cite

Therapy of allergic diseases in children implicates avoidance of allergens, standard pharmacotherapy, and immunotherapy. Immunotherapy is the only treatment for allergic diseases with the ability to change the natural course of the disease, thus stopping its further progression as well as the development of new allergic diseases and new sensibilizations. The objective of this chapter is to give insight into the latest data on immunotherapy in treating children with allergic diseases. Methods: The study involved a search for relevant articles on the MEDLINE and PubMed up to 2017. Results: Numerous studies have shown that the sublingual application of allergen-specific immunotherapy is adequate, safe, and efficient in the therapy of immunoglobulin E (IgE)-mediated allergic diseases of the respiratory tract in children, but there are still some questions to be solved concerning the usage of SLIT in children younger than 5 years old, SLIT for polysensitized patients, duration of SLIT, long-lasting effects of SLIT. Conclusions: In order to improve the clinical efficacy of SLIT, we are looking for new routes of administration, new allergens, new protocols as well as combination of SLIT with other immune modulatory treatments.

show abstract

Inhaled allergen bronchoprovocation tests

Cited by 108 publications

References 116 publications

Allergen-Induced Asthmatic Responses Modified by a GATA3-Specific DNAzyme

Allergen-Induced Asthmatic Responses Modified by a GATA3-Specific DNAzyme

Btk Inhibitor RN983 Delivered by Dry Powder Nose-only Aerosol Inhalation Inhibits Bronchoconstriction and Pulmonary Inflammation in the Ovalbumin Allergic Mouse Model of Asthma

Current Issues on Immunotherapy in Children

Contact Info

Product

Resources

About